Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 12Lymphoid 11Gastrointestinal 11Genitourinary 10CNS 9Other hematologic neoplasm 8Myeloid 7Breast 6Plasma cell 5Head & Neck 5Gynecologic 5Tumor-Agnostic 3Thoracic 3Endocrine 3NET 2Dermatologic 2Other neoplasm 1

Conditions

Thyroid Cancer, Papillary 1Neuroendocrine Tumors 1Advanced Lung Neuroendocrine Tumor 1Adenocarcinoma, Follicular 1

Interventions

Specimen Handling 10Magnetic Resonance Spectroscopy 10lutetium Lu 177 dotatate 8cabozantinib 4Nivolumab 4Cisplatin 4pembrolizumab 3X-Rays 3Ipilimumab 3Everolimus 3Etoposide 3Carboplatin 3olaparib 2gallium Ga 68 dotatate 2fluorodopa F 18 2fludarabine 2aldesleukin 2Phantoms, Imaging 2Lutetium-177 2Lutetium 2Irinotecan 2Fluorodeoxyglucose F18 2Cyclophosphamide 2CTLA-4 Antigen 2trametinib 1tipifarnib 1sodium thiosulfate 1selpercatinib 1repotrectinib 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
X-Rays × Endocrine × 30 days × Clear all
NCT01841736 2026-05-27

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
171 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT06959641 2026-05-22

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Northwestern University

Phase 2 Recruiting
33 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡